# Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

> **NCT02836418** · PHASE1,PHASE2 · COMPLETED · sponsor: **aTyr Pharma, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Facioscapulohumeral Muscular Dystrophy
- Limb Girdle Muscular Dystrophy

## Interventions

- **DRUG:** ATYR1940

## Key facts

- **NCT ID:** NCT02836418
- **Lead sponsor:** aTyr Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-13
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-04-18
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836418, "Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02836418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*